Cardiol Therapeutics Files 6-K for February 2025
Ticker: CRDL · Form: 6-K · Filed: Feb 20, 2025 · CIK: 1702123
Sentiment: neutral
Topics: regulatory-filing, news-release
TL;DR
Cardiol Therapeutics filed a 6-K on Feb 20, 2025, with a news release attached.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on February 20, 2025, reporting for the month of February 2025. The filing, submitted by newsfilecorp.com, includes Exhibit 99.1, which is a news release. The company is incorporated in Canada and its principal executive offices are located in Oakville, Ontario.
Why It Matters
This filing indicates ongoing reporting activity for Cardiol Therapeutics, which is relevant for investors monitoring the company's communications and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily contains a news release and does not appear to disclose significant new financial or operational risks.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer of the 6-K report
- newsfilecorp.com (company) — Entity that filed the Form 6-K
- February 2025 (date) — Reporting period for the Form 6-K
- February 20, 2025 (date) — Filing date of the Form 6-K
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K is to report for the month of February 2025 and includes Exhibit 99.1, which is a news release from Cardiol Therapeutics Inc.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on February 20, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Does Cardiol Therapeutics file annual reports under Form 20-F or Form 40-F?
Cardiol Therapeutics indicates it files annual reports under Form 20-F.
What exhibit is submitted with this Form 6-K?
Exhibit 99.1, a News Release, is submitted with this Form 6-K.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 20, 2025 regarding Cardiol Therapeutics Inc. (CRDL).